Seres Therapeutics conducts clinical trials to study the safety and efficacy of our investigational drugs for the treatment of diseases resulting from disruption to the microbiome, a condition known as dysbiosis.
Our proprietary microbiome therapeutics platform enables us to discover and develop our microbiome therapeutic candidates. These therapies are designed to target the functional deficiencies in a dysbiotic microbiome, and to deliver the keystone features needed to disrupt the disease microbiome and catalyze the transition of the gut microbiota to a healthy state.
These therapies have the potential to improve the lives of patients who are suffering from diseases for which the current course of treatment is inadequate, or for which no treatment exists.
We are currently conducting the following clinical trials:
- SER-109: A Phase 3 Study (ECOSPOR III) to evaluate the safety and efficacy of SER-109 versus placebo. ECOSPOR III incorporates direct learnings from prior SER-109 development efforts. The study is expected to enroll approximately 320 patients with multiply recurrent C. difficile infection, randomized 1:1 to either SER-109 or placebo. The study is sized to contribute to an adequate safety database that may support product licensure. ECOSPOR III will utilize more than 100 clinical sites across the U.S. and Canada. The study’s primary endpoint will compare the reduction of C. difficile recurrence rates in subjects who receive SER-109 verses placebo at up to eight weeks after dosing.
- SER-287: SERES-101 Study: A Phase 1b clinical study evaluating the safety and efficacy of SER-287 versus placebo, in adults with mild-to-moderate ulcerative colitis (UC) (SERES-101 Study)
- SER-262: SERES-001 Study: A current Phase 1b study evaluating the safety and efficacy of SER-262 versus placebo, in adults with primary Clostridium difficile infection to prevent recurrence. (SER-262-001 Study)
The following clinical trials have been completed:
- SER-109, Phase 1b open-label, single-arm, descending-dose study
- SER-109, ECOSPORTM Study: A RandomizEd, Double Blind, Placebo COntrolled, Parallel Group Study of SER 109 to Prevent Recurrent ClOstRidium difficile Infection (SERES-004 Study)
Seres Therapeutics is a proud collaborator to organizations raising awareness for and supporting research in our disease focus areas.
Learn more about these important organizations at the links below.
Clostridium difficile infection
Inflammatory Bowel Disease